Related Experiment Video
Updated: Jul 4, 2026
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
PPARgamma in Neuroblastoma.
Alessandro Peri1, Ilaria Cellai, Susanna Benvenuti
1Endocrine Unit, Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders (DENOThe), University of Florence, 50139 Florence, Italy.
Neuroblastoma (NB), a common childhood cancer, has poor outcomes in high-risk patients. This review examines how peroxisome proliferator-activated receptor gamma (PPARgamma) agonists may offer new therapeutic strategies for NB.
Area of Science:
- Pediatric Oncology
- Molecular Biology
- Cancer Research
Background:
- Neuroblastoma (NB) is the most frequent extracranial childhood tumor, causing 15% of pediatric cancer deaths.
- Advanced NB stages and high-risk features lead to poor prognoses despite aggressive treatments like surgery, chemotherapy, and radiotherapy.
Purpose of the Study:
- To review the role and mechanisms of peroxisome proliferator-activated receptor gamma (PPARgamma) in neuroblastoma cells.
- To explore the potential of PPARgamma agonists as a novel therapeutic approach for NB.
Main Methods:
- Literature review of studies investigating PPARgamma in neuroblastoma.
- Analysis of existing research on the antineoplastic effects of PPARgamma agonists.
Main Results:
- PPARgamma agonists demonstrate pleiotropic effects, including potential antineoplastic activities.
- Evidence suggests PPARgamma plays a role in NB cell biology and may be a therapeutic target.
Conclusions:
- PPARgamma agonists represent a promising avenue for developing new treatments for neuroblastoma.
- Further research into PPARgamma's mechanisms in NB could lead to improved patient outcomes.
